Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | FNTA | P49354 | 3/20 | 0.42 |
| ▸ | FNTB | P49356 | 3/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5200105 | 1.00 | NR1I2 (0.56) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL30555741 | 0.98 | NR1I2 (0.58) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2836272 | 0.89 | NR1I2 (0.42) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2835848 | 0.86 | PTGS1 (0.46) | NR1I2LMNAPGRALOX15ALDH1A1 | |
| SCHEMBL2832404 | 0.85 | NR1I2 (0.62) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2835821 | 0.85 | NR1I2 (0.62) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2838626 | 0.85 | NR1I2 (0.62) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2833656 | 0.82 | NR1I2 (0.66) | NR1I2LMNAPGRFNTAFNTB | |
| SCHEMBL2838889 | 0.82 | PTGS1 (0.36) | NR1I2LMNAPGRALOX15ALDH1A1 | |
| SCHEMBL2837914 | 0.81 | LMNA (0.55) | NR1I2LMNAPGRFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866323-B1 | GLUCURONIDATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-1848424-B1 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LAB INC (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2808015-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2014-12-03 | — | — | EP | disclosed |
| US-7838552-B2 | Compositions comprising nebivolol | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2010-11-23 | — | — | US | disclosed |
| EP-2174658-A1 | Compositions comprising nebivolol | MYLAN LABORATORIES, INC (US) | 2010-04-14 | — | — | EP | disclosed |
| EP-1982711-A1 | Compositions comprsing nebivolol | MYLAN LABORATORIES, INC (US) | 2008-10-22 | — | — | EP | disclosed |
| US-20080161296-A1 | Compositions comprising nebivolol | DEY, INC. (F/K/A DEY LABORATORIES, INC.) | 2008-07-03 | — | — | US | disclosed |
| EP-1890691-A2 | COMPOSITIONS COMRISING NEBIVOLOL | MYLAN LABORATORIES, INC (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1866323-A2 | GLUCURONIDATED NEBIVOLOL | MYLAN LABORATORIES, INC (US) | 2007-12-19 | — | — | EP | disclosed |
| EP-1848424-A2 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LABORATORIES, INC (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006130174-A2 | COMPOSITIONS COMRISING NEBIVOLOL | MYLAN LABORATORIES, INC. (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006083779-A2 | PHARMACEUTICAL COMPOSITION COMPRISING HYDROXYLATED NEBIVOLOL | MYLAN LABORATORIES, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006083780-A2 | GLUCURONIDATED NEBIVOLOL | MYLAN LABORATORIES, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161296-A1 | Compositions comprising nebivolol | ADRB1, ADRB3, ADRB2 | NR1I2 554/4885LMNA 185/4885PGR 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.